Betagistin

General characteristics. Structure:

Active ingredient: 0,008 g, 0,016 g or 0,024 g of a betagistin of dihydrochloride in 1 tablet.

Excipients: sodium of a kroskarmelloz; sodium lauryl sulfate; cellulose microcrystallic; citric acid; magnesium stearate.

It is applied to stopping of attacks of vestibular dizziness, decrease in frequency and intensity of dizzinesses, reduction of a sonitus, improvement of hearing in case of its decrease.

Pharmacological properties:

Pharmacodynamics. The antagonist of H1 - histamine receptors of vessels of an inner ear and the antagonist of H3 - histamine receptors of vestibular nuclei of the central nervous system (CNS). Due to relaxation of precapillary sphincters of vessels of an inner ear improves blood circulation in a vascular stripe of an inner ear.

Dozozavisimo reduces generation of action potentials in neurons of lateral and medial vestibular nuclei. Accelerates recovery of vestibular function after a unilateral vestibular neurectomy, accelerating and facilitating the central vestibular compensation (due to antagonism with H3 - histamine receptors). Facilitates symptomatology at Menyer's syndrome and vestibular dizziness.

The stable therapeutic effect occurs in 14 days.

Pharmacokinetics. Communication with proteins of plasma – low, less than 5% is absorbed quickly. The maximum concentration in a blood plasma (Cmax) is reached in 1 hour. It is metabolized to inactive metabolites: 2-pyridylacetic acid (main metabolite) and demetilbetagistina. Almost completely (to 85-90%) it is brought by kidneys in the form of a metabolite (2-peridiluksusny acid) within 24 hours.

Removal of a betagistin and demetilbetagistin kidneys slightly. Intestines remove only a small part of a betagistin and its metabolites.

Indications to use:

The treatment of a syndrome of Menyer who is characterized by dizziness (which is followed by nausea and vomiting), decrease in hearing and a sonitus. Symptomatic treatment of vestibular dizziness (вертиго).

Route of administration and doses:

Inside, during food.

Tablets of 8 mg: on 1-2 tablets 3 times a day.

Tablets of 16 mg: ½ - 1 tablet 3 times a day.

Tablet of 24 mg: on 1 tablet 2 times a day.

The course of treatment is defined individually. Improvement is usually noted already at the beginning of therapy, stable the therapeutic effect occurs after two weeks of treatment and can increase within several months of treatment. Prolonged treatment. Duration of administration of drug is selected individually.

Features of use:

Use at pregnancy and during breastfeeding. Drug is contraindicated to use during pregnancy as also the fruit there are not enough data for assessment of impact of drug on pregnant women. During a lactation drug should not be used or for the period of treatment it is necessary to stop breastfeeding.

The therapeutic effect in some cases increases within several months from an initiation of treatment.

Influence on ability to driving or other mechanical means. Betagistin does not possess sedation and does not influence ability to drive the car or to work at machines and mechanisms.

Side effects:

Frequency: often – more than 1/100 and less than 1/10.

From the alimentary system: often – nausea, dyspepsia.

Post-marketing experience:

Allergic reactions: hypersensitivity (including, anaphylactic reactions, Quincke's disease, skin rash, small tortoiseshell, Quincke's edema).

From the alimentary system: vomiting, abdominal pain, abdominal distention.

From integuments: itch.

Interaction with other medicines:

Cases of interaction or incompatibility with other HP are unknown.

Contraindications:

Hypersensitivity to one of drug components, children up to 18 years (due to the lack of data), pregnancy, the lactation period.

With care: a peptic ulcer of a stomach or a 12-perstny gut (in the anamnesis), a feokhromitsitoma, bronchial asthma.

Overdose:

Symptoms: nausea, vomiting, abdominal pain, drowsiness (at reception in a dose to 640 mg); spasms, cardiopulmonary complications (at reception in a dose more than 640 mg or in combination with other medicines (M).

Treatment: gastric lavage, reception of absorbent carbon, symptomatic therapy.

Storage conditions:

Period of validity - 2 years. Not to use after the period of validity specified on packaging. In the dry, protected from light place at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Mg tablets 8, 16, 24. On 5, 7, 10, 14, 15, 20, 30 tablets in a blister strip packaging from a film of the polyvinyl chloride and printing aluminum foil varnished. On 1, 2, 3, 4, 5, 6 blister strip packagings together with the application instruction place in a pack from a cardboard.